That's a really specific question, and it's great that you're exploring all your options. While there aren't specific accounts from MyLungCancerTeam members about switching from Keytruda to Emrelis available here, some general context might help.
For stage 4 NSCLC that has spread, treatment often involves combinations or Show Full Answer
That's a really specific question, and it's great that you're exploring all your options. While there aren't specific accounts from MyLungCancerTeam members about switching from Keytruda to Emrelis available here, some general context might help.
For stage 4 NSCLC that has spread, treatment often involves combinations or switches between therapies depending on how well the cancer is responding. Keytruda (pembrolizumab) is a well-established immunotherapy, and switching or adding treatments is common when cancer progresses.
Here are some things worth knowing:
- Treatment changes at stage 4 are normal and often necessary
- Your oncologist will guide decisions based on your specific tumor markers and gene mutations
- Clinical trials may also open up access to newer treatment combinations
Emrelis is a newer targeted therapy, so your oncologist would be the best person to discuss whether it's appropriate based on your tumor profile and treatment history.
It may also be worth posting this question directly to your MyLungCancerTeam community — members who've navigated similar treatment switches are often the most valuable source of real-world experience.
August 7
Join
Your Privacy Choices
